GSA Capital Partners’s Atossa Therapeutics ATOS Stock Holding History

GSA Capital Partners’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,717	Closed	-$269K	–	1669
2025 Q3	$269K	Buy	20,717 +17,315	+509%	+$214K	0.02%	1261
2025 Q2	$42K	Buy	+3,402	New	+$40.7K	﹤0.01%	1668
2024 Q1	–	Sell	-29,939	Closed	-$395K	–	1594
2023 Q4	$395K	Buy	29,939 +6,780	+29%	+$73.1K	0.03%	954
2023 Q3	$256K	Buy	23,159 +2,985	+15%	+$43.3K	0.02%	1165
2023 Q2	$381K	Buy	+20,174	New	+$245K	0.04%	907
2022 Q4	–	Sell	-4,793	Closed	-$60K	–	1454
2022 Q3	$60K	Buy	+4,793	New	+$69.6K	0.01%	1409
2022 Q2	–	Sell	-4,415	Closed	-$83K	–	1390
2022 Q1	$83K	Buy	+4,415	New	+$89.7K	0.01%	1311
2021 Q2	–	Sell	-1,528	Closed	-$48K	–	1310
2021 Q1	$48K	Buy	+1,528	New	+$55.8K	0.01%	1031

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

GSA Capital Partners's ATOS Position: Q4 2025 in Review

GSA Capital Partners sold out of Atossa Therapeutics (ATOS) in Q4 2025, closing a stake of 20,717 shares — an estimated $269K sold.

GSA Capital Partners first reported a position in ATOS in Q1 2021 and held it in 8 quarters. The position peaked at $395K in Q4 2023. 67 funds tracked by Wall St. Rank hold ATOS as of Q4 2025.

GSA Capital Partners reported no remaining Atossa Therapeutics position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 20,717 Atossa Therapeutics shares in Q4 2025, an estimated $269K.
GSA Capital Partners first reported a position in Atossa Therapeutics in Q1 2021 and held it in 8 quarters.
GSA Capital Partners's Atossa Therapeutics position peaked at $395K in Q4 2023.
67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.